Australian-led PCOS guideline an international first

Medical Journal of Australia, Published online: 22 November 2019

An Australian-led international and multidisciplinary collaboration of health professionals and consumers has produced the first international evidence-based guideline for the diagnosis and management of polycystic ovary syndrome (PCOS) with an unprecedented international translation program, summarised today in a supplement published by the Medical Journal of Australia.

Led by Professor Helena Teede, Director of the National Health and Medical Research Council Centre for Research Excellence in PCOS, Monash and Adelaide Universities, the collaborators took 2 years to write the guideline, which includes an integrated translation program incorporating resources for health professionals and consumers.

PCOS affects 8–13% of reproductive age women, with around 21% of Indigenous women affected.

Intersex Peer Support Australia launches

Intersex Peer Support Australia (IPSA), 25th October 2019

On the eve of Intersex Awareness Day, an internationally observed awareness day designed to highlight human rights issues faced by intersex people, and observed on 26 October each year, one of the oldest intersex groups in the world is launching a new name, branding and website.

Intersex Peer Support Australia (IPSA) will carry on the important work of the 1985-founded Androgen Insensitivity Syndrome Support Group Australia (AISSGA), which for more than three decades has been dedicated to assisting people born with variations in sex characteristics and their families, providing Australia-wide peer support, information and advocacy.

Elise Nyhuis, President of IPSA said, “The new identity will make us more visible to government agencies and support funders, and is more inclusive of the more than 40 known intersex variations, our diverse community and their families.”

“Our organisation advocates for and provides peer support to its members and the wider intersex community, focusing on the lived experience of having intersex bodies that physically differ from stereotypical, medical notions of male and female.

“The intersex community in Australia is strong and growing as people come out of hiding to stand together in the face of continued challenges from medicalisation, stigma and discrimination, shame, mental health issues, social inclusion, access to affirmative healthcare, parenting and human rights protection from medically unnecessary medical interventions on intersex children.

“Beyond our core work of providing intersex peer support, IPSA advocates for intersex issues through educating service providers, liaising with medical professionals, conducting policy review and consulting with government and NGOs, as well as by building community through coordinating opportunities and events for people with intersex variations to meet and share knowledge and experiences.

“The updated IPSA website will be a great resource for the whole community to learn more about the ‘I’ in the LGBTIQ acronym, while our membership will have access to a range of online extras through password-secured access,” said Elise.

Women taking pill may be less likely to suffer ACL injury, study finds

The Guardian,

Disorders of penis development are on the rise and we’re not sure why

By Mark Green and Andrew Pask

In prenatal ultrasounds or at delivery, many new parents look between their baby’s legs: the presence of a penis is taken as a strong sign that it’s a boy.

For humans and other animals, development of a penis was thought to be driven by “male hormones” (androgens) produced entirely by the testes of the male fetus as it grows in the uterus.

However, a new paper released today indicates this might not be the case.

Clinical Education Forum: Menopause, mood and missing mojo

SHINE SA, 15/01/2019

SHINE SA is pleased to present the following Clinical Education Forum on the topic of ‘Menopause, mood and missing mojo’.

This forum is available free of charge, and will also be recorded for future access.

This forum will cover management of menopause and a discussion of perimenopausal mood disorder and sexual dysfunction.

PRESENTER: Dr Amy Moten, SHINE SA Coordinator: Medical Education.

COST: Free. Light meal will be provided.
DATES: 5 February 2019
TIME: 6pm registration, 6.30 – 8.30pm
LOCATION: SHINE SA, 64c Woodville Road, Woodville

CPD points are awarded on completion of this forum

Enrol now via this page https://www.shinesa.org.au/events/education-forums/

 

 

 

Transgender women taking PrEP have lower levels of PrEP drugs than cisgender men

aidsmap/nam, November 9th 2018

A study presented at October’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in their blood that are about 25% lower than those in cisgender men, and levels in rectal tissue cells about 40% lower. Tenofovir levels in rectal tissue were 44% lower.

However, the study also confirmed that the interaction between hormones and PrEP did not appear to go the other way; blood levels of estradiol, the one hormone all of the transgender women took in one form or another, do not appear to be affected by PrEP.